Invest in Oslo - Life Sciences & Healthtech Industry
Dealroom Facts & Numbers
Three promising companies from Oslo:
- EpiGuard is a Norwegian company established in 2015 by a group of doctors. Their team of medical experts and engineers develops state-of-the-art products that provide better solutions for the safe transportation of contagious patients. The company won the Oslo Innovation Award at Oslo Innovation Week 2021 and currently has total funding of €6.2m according to Dealroom. (Photo: Ellen Cathrine Andersen - Epiguard)
- Nykode Therapeutics (formerly known as Vaccibody) is a leading clinical-stage biopharmaceutical company that is dedicated to the discovery and development of vaccines and new immunotherapies for the future of medicine through their intelligent modular design and tailored hyper-targeting. According to Dealroom, the company has an overall investment of €32.1m.
- Nextera is a drug and target discovery company offering a unique approach to improved therapeutic intervention for major diseases such as autoimmunity, chronic inflammatory disorders, and cancer. In December 2020, the Norwegian Research Council awarded a prestigious grant for 15.7 MNOK (€2.5m) funding to expand their NextCore platform. They are also backed by Birk Venture.
Opportunities in Life Sciences & Healthtech
Since 2010, life sciences and healthtech have experienced steady growth, leading to exceptional discoveries that address previously unmet medical demands and improve the life quality of people around the world. With the current COVID-19 pandemic, the sector has drawn increasing attention, creating a wave of opportunities for innovation and an increasing desire among investors and governmental authorities to invest in this sector.
Leading scientific research, renowned technology expertise, and early adoption of technology make Norway one of the fastest-growing environments for innovation in healthtech, medtech, care-tech, digital health, and pharma. An ideal platform for launching innovations that address universal global needs, Norway is attracting the attention of key investors and corporates.
One of every three health startups is born global. This means that ideas, solutions and products should be global from day one. Oslo provides a solid platform for groundbreaking ideas that can be implemented globally.
According to the Private Equity Funds in Norway Activity Report 2020 by Menon, Norwegian PE firms' investments for Life Science in 2020 was NOK 550 million and the number of investments by Norwegian PE Firms was 33.
While VCs focusing on life sciences and healthtech are uncommon in Norway, there are a dozen family offices that are very active in healthcare. The investment scene is actively mobilized by platforms such as The Norwegian Health Investor Network.
Norwegian investment managers like Arctic Aurora LifeScience also conduct active portfolio management with a focus on innovative companies in the healthcare sector with an emphasis on biotech and pharmaceuticals companies in Europe and the United States of America.
How do we support?
Oslo Business Region is working closely with the hubs focusing on health and life science in Oslo. For example, through Oslo Innovation Week and a project in partnership with Oslo Science Cluster to attract investors to health and life science companies in Oslo.
For example, events at Oslo Innovation Week and a project in partnership with Oslo Science Cluster aimed at attracting investors to health and life science companies in Oslo. Companies such as Epiguard, the recipient of the OIW Innovation Award, are showcased nationally and internationally.